Artiva Biotherapeutics Says It Is Initiating Phase 3 Trial Of AlloNK Plus Rituximab In About 150 Refractory RA Patients In H2 2026; Expects Updated Phase 2a Data From At Least 20 RA Patients In H2 2026

Loading news article.

Artiva Biotherapeutics Says It Is Initiating Phase 3 Trial Of AlloNK Plus Rituximab In About 150 Refractory RA Patients In H2 2026; Expects Updated Phase 2a Data From At Least 20 RA Patients In H2 2026 | WAPE

Artiva Biotherapeutics Says It Is Initiating Phase 3 Trial Of AlloNK Plus Rituximab In About 150 Refractory RA Patients In H2 2026; Expects Updated Phase 2a Data From At Least 20 RA Patients In H2 2026

Article summary

Related companies

Analyzed by WAPE AI.

Comments —